Block of the background K(+) channel TASK-1 contributes to arrhythmogenic effects of platelet-activating factor

Am J Physiol Heart Circ Physiol. 2002 Jun;282(6):H2024-30. doi: 10.1152/ajpheart.00956.2001.

Abstract

Platelet-activating factor (PAF), an inflammatory phospholipid, induces ventricular arrhythmia via an unknown ionic mechanism. We can now link PAF-mediated cardiac electrophysiological effects to inhibition of a two-pore domain K(+) channel [TWIK-related acid-sensitive K(+) background channel (TASK-1)]. Superfusion of carbamyl-PAF (C-PAF), a stable analog of PAF, over murine ventricular myocytes causes abnormal automaticity, plateau phase arrest of the action potential, and early afterdepolarizations in paced and quiescent cells from wild-type but not PAF receptor knockout mice. C-PAF-dependent currents are insensitive to Cs(+) and are outwardly rectifying with biophysical properties consistent with a K(+)-selective channel. The current is blocked by TASK-1 inhibitors, including protons, Ba(2+), Zn(2+), and methanandamide, a stable analog of the endogenous lipid ligand of cannabinoid receptors. In addition, when TASK-1 is expressed in CHO cells that express an endogenous PAF receptor, superfusion of C-PAF decreases the expressed current. Like C-PAF, methanandamide evoked spontaneous activity in quiescent myocytes. C-PAF- and methanandamide-sensitive currents are blocked by a specific protein kinase C (PKC) inhibitor, implying overlapping signaling pathways. In conclusion, C-PAF blocks TASK-1 or a closely related channel, the effect is PKC dependent, and the inhibition alters the electrical activity of myocytes in ways that would be arrhythmogenic in the intact heart.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Action Potentials / drug effects
  • Animals
  • Arachidonic Acids / pharmacology
  • Arrhythmias, Cardiac / chemically induced*
  • Arrhythmias, Cardiac / physiopathology
  • Barium / pharmacology
  • Electric Conductivity
  • Electrophysiology
  • Enzyme Inhibitors / pharmacology
  • Heart / physiopathology
  • Heart Ventricles / ultrastructure
  • Membrane Potentials / drug effects
  • Mice
  • Mice, Knockout
  • Nerve Tissue Proteins*
  • Phospholipid Ethers
  • Platelet Activating Factor / pharmacology*
  • Platelet Membrane Glycoproteins / deficiency
  • Platelet Membrane Glycoproteins / physiology
  • Potassium Channel Blockers*
  • Potassium Channels / physiology
  • Potassium Channels, Tandem Pore Domain*
  • Protein Kinase C / antagonists & inhibitors
  • Protons
  • Receptors, Cell Surface*
  • Receptors, G-Protein-Coupled*
  • Zinc / pharmacology

Substances

  • Arachidonic Acids
  • Enzyme Inhibitors
  • Nerve Tissue Proteins
  • Phospholipid Ethers
  • Platelet Activating Factor
  • Platelet Membrane Glycoproteins
  • Potassium Channel Blockers
  • Potassium Channels
  • Potassium Channels, Tandem Pore Domain
  • Protons
  • Receptors, Cell Surface
  • Receptors, G-Protein-Coupled
  • platelet activating factor receptor
  • 1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine
  • methanandamide
  • potassium channel subfamily K member 3
  • Barium
  • Protein Kinase C
  • Zinc